Ignite Creation Date:
2025-12-25 @ 1:27 AM
Ignite Modification Date:
2025-12-28 @ 10:29 PM
Study NCT ID:
NCT01101594
Status:
TERMINATED
Last Update Posted:
2021-08-16
First Post:
2010-03-11
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma
Sponsor:
Gilead Sciences
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2010-07
Start Date Type:
None
Primary Completion Date:
2013-07
Primary Completion Date Type:
ACTUAL
Completion Date:
2013-07
Completion Date Type:
ACTUAL
First Submit Date:
2010-03-11
First Submit QC Date:
None
Study First Post Date:
2010-04-12
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
2021-08-16
Disp First Post Date Type:
ACTUAL
Last Update Submit Date:
2021-08-12
Last Update Post Date:
2021-08-16
Last Update Post Date Type:
ACTUAL